Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
Details
The document's own metadata, straight from the source system.
- Title
- Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
- Posted
- May 26, 2026
- Comment period
- May 26, 2026 – Jun 26, 2026
- FR Doc
- 2026-10380
- CFR
- 21 CFR Part 1308
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 24, 2026Miranda CraftSupportIndividual
A registered nurse supports the DEA's proposal to classify diphenidine as a Schedule I controlled substance. The commenter argues that the drug has no accepted medicinal use, a high potential for abuse, and severe adverse effects similar to PCP.
Read comment → - Jun 19, 2026Matthew LutherOpposeIndividual
The commenter opposes placing diphenidine in Schedule I because they believe the restrictive regulations would hinder scientific research into its pharmacological and therapeutic potential. They suggest the DEA consider a less restrictive scheduling category that balances public safety with the need for scientific inquiry.
Read comment →